



FULBRIGHT & JAWORSKI L.L.P.


A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

RECEIVED
FEB 04 2003
TECH CENTER 1600/2909

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3180
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

January 17, 2003

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
January 17, 2003 Date	 Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 09/981,682 entitled "METHOD OF INHIBITING VIRAL INFECTION USING HMG-COA REDUCTASE INHIBITORS AND ISOPRENYLATION INHIBITORS" by Barney Scott Graham et al.*
F&J Reference: VBLT:003US / 10108410


Commissioner:

Please find enclosed:

1. Response to Restriction Requirement Dated December 17, 2002; and
2. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Deposit Account No.: 50-1212/10108410/VBLT:003US.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/fb
Encl.: as noted

25253186.1

BEST AVAILABLE COPY



#11
2/5/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT
RECEIVED
FEB 04 2003
TECH CENTER 1600/2900

In re Application of:
Barney Scott GRAHAM *et al.*

Serial No.: 09/981,682

Filed: October 16, 2001

For: METHOD OF INHIBITING VIRAL
INFECTION USING HMG-COA
REDUCTASE INHIBITORS AND
ISOPRENYLATION INHIBITORS

Group Art Unit: 1617

Examiner: S. A. Jiang

Atty. Dkt. No.: VBLT:003US

CERTIFICATE OF MAILING 37 C.F.R. §1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
January 17, 2003	
Date	Steven L. Highlander

RESPONSE TO RESTRICTION REQUIREMENT DATED DECEMBER 17, 2002

Hon. Commissioner for Patents
Washington, D.C. 20231


Sir:

This is in response to the Restriction Requirement mailed December 17, 2002, with respect to the above-captioned application. The deadline for response is January 17, 2003. No fees are believed to be due in connection with the filing of this paper; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10108410/SLH.

Applicants elect, without traverse, the invention of Group I, claims 1-20. With respect to the first election of species requirement, applicants elect without traverse infections with RSV. Claims 1-9, 11 and 13-20 read on the elected invention. Claims 1-9, 13-16, 18 and 19 are generic. With respect to the second election of species requirement, applicants election without traverse the active compound lovastatin. Claims 1-20 read on the elected species and are generic.

Should there be any question regarding this response, a telephone call to the undersigned is invited.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: January 17, 2003